Holen Sie sich die Stockscreener-App
2.12
6.00%
0.12
Handel nachbörslich:
2.13
0.010
+0.47%
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics management to join Needham Healthcare Conference fireside chat April 13 - Traders Union
Neumora Therapeutics to Participate in 25th Annual Needham Virtual Healthcare Conference - The Manila Times
If You Invested $1,000 in Neumora Therapeutics Inc (NMRA) - Stock Titan
Financial intelligence spearheads cross-departmental progress at Neumora Therapeutics - Traders Union
Q2 EPS Forecast for Neumora Therapeutics Boosted by Analyst - MarketBeat
ARCH funds detail Neumora (NASDAQ: NMRA) ownership near 19% stake - Stock Titan
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the ... - Bluefield Daily Telegraph
NMRA Investors Have Opportunity to Join Neumora Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - globenewswire.com
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), Neumora Therapeutics, Inc. (NMRA) and Gain Therapeutics (GANX) - The Globe and Mail
Neumora Therapeutics, Inc. (NMRA) Gets a Buy from Guggenheim - The Globe and Mail
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Neumora Therapeutics Maps High-Stakes Catalyst Road Ahead - tipranks.com
Loss Report: Will Neumora Therapeutics Inc benefit from geopolitical trendsQuarterly Market Summary & Trade Opportunity Analysis - baoquankhu1.vn
Guggenheim Reaffirms "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
A Quick Look at Today's Ratings for Neumora Therapeutics(NMRA.US), With a Forecast Between $6 to $18 - Moomoo
Neumora Therapeutics' (NMRA) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
Neumora Therapeutics Warns Nasdaq Delisting Risk Could Hit Liquidity, Share Price, and Capital Access - tipranks.com
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% By Investing.com - Investing.com India
Neumora tops Q4 earnings forecasts as pipeline advances, shares slip - MSN
Guggenheim reiterates Neumora stock rating on pipeline progress By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Neumora Therapeutic (NMRA.US) will release its earnings report before the market opens on March 30. - Moomoo
Neumora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Neumora Therapeutics: Downgrading After Navacaprant Development Setback (NASDAQ:NMRA) - Seeking Alpha
Neumora Therapeutics 2025 Financial Update - AlphaStreet
Neumora Therapeutics Reports Strong 2025 Financials and Clinical Pipeline Progress Including NMRA-511 Alzheimer’s Agitation Data and KOASTAL-2/3 Enrollment 123 - Minichart
Stifel reiterates Neumora Therapeutics stock Hold rating at $3 By Investing.com - ca.investing.com
Neumora Therapeutics Sees Unusually Large Options Volume (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics Q4 2025 Earnings Call Transcript - MarketBeat
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Neumora 2025 10-K Report: Precision Neuroscience, Intellectual Property, and Business Overview - Minichart
Neumora Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: Neumora Therapeutics beats Q4 2025 EPS forecast, stock dips - investing.com
Neumora Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Neumora beats Q4 earnings expectations amid pipeline progress, stock falls 2% - au.investing.com
Neumora Therapeutics, Inc. (NMRA) Q4 FY2025 earnings call transcript - Yahoo Finance
Neumora Therapeutics (NASDAQ:NMRA) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Neumora (NASDAQ: NMRA) maps key 2026–27 milestones for depression, Alzheimer’s and obesity drugs - Stock Titan
Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
Neumora (NMRA) posts 2025 loss, advances CNS pipeline with key 2026–27 milestones - Stock Titan
With 400-plus in each trial, Neumora heads for a Q2 drug readout - Stock Titan
NMRA PE Ratio & Valuation, Is NMRA Overvalued - Intellectia AI
Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies - MSN
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Neumora Therapeutics (NMRA) price target decreased by 16.15% to 7.82 - MSN
Neumora Therapeutics gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts - MSN
Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most - Benzinga
Neumora Therapeutics Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Neumora Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Sahm
Does Neumora Therapeutics Inc stock have upside surprise potential2026 Levels & Consistent Growth Stock Picks - baoquankhu1.vn
Neumora Therapeutic (NMRA.US) will release its earnings report on March 30. - Moomoo
Neumora Therapeutics stock jumps, analyst sees upside in Alzheimer's treatment - MSN
NMRA SEC FilingsNeumora Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neumora Therapeutics (NMRA) positioned to capitalize on blockbuster opportunity - MSN
Quarterly Trades: Is Neumora Therapeutics Inc forming a breakout pattern2026 Investor Takeaways & Daily Profit Maximizing Tips - baoquankhu1.vn
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):